Trimethylammonium

Trimethylammonium

SCHEMBL4940112

CC(C)C(C)(N)C(C)C.CN(C)C

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980 0.89
Iodide SCHEMBL115030 0.85
SCHEMBL27764889 0.85
SCHEMBL28154308 0.85
Fluoride SCHEMBL73857 0.85
Hydrochloric Acid SCHEMBL366445 0.85
Chloromethane SCHEMBL29210875 0.85
Ammonia Solution, Strong SCHEMBL4950713 0.85
Fluoride SCHEMBL1025919 0.85
Methane SCHEMBL28271988 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230390322-A1 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-12-07 US disclosed
WO-2022081601-A1 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXY-COBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-04-21 WO disclosed
US-20080039422-A1 Vitamin B12-Containing Compositions and Methods of Use TRANSITION THERAPEUTICS INC. (CA) 2008-02-14 US disclosed
WO-2003045969-A1 COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY AVECIA BIOTECHNOLOGY INC. (US) 2003-06-05 WO disclosed